GenSight Biologics S.A.
SIGHT.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €25,854 | €22,226 | €155,762 | €251,037 |
| - Cash | €2,464 | €2,134 | €10,610 | €44,288 |
| + Debt | €19,113 | €23,535 | €12,647 | €12,566 |
| Enterprise Value | €42,503 | €43,627 | €157,799 | €219,315 |
| Revenue | €2,625 | €1,267 | €2,582 | €5,276 |
| % Growth | 107.2% | -50.9% | -51.1% | – |
| Gross Profit | €2,625 | €3,000 | €2,582 | €5,276 |
| % Margin | 100% | 236.8% | 100% | 100% |
| EBITDA | -€14,755 | -€21,730 | -€26,774 | -€25,521 |
| % Margin | -562.1% | -1,715.1% | -1,036.9% | -483.7% |
| Net Income | -€14,001 | -€26,220 | -€27,624 | -€28,617 |
| % Margin | -533.4% | -2,069.5% | -1,069.9% | -542.4% |
| EPS Diluted | -0.15 | -0.54 | -0.6 | -0.63 |
| % Growth | 72.2% | 10% | 4.8% | – |
| Operating Cash Flow | -€12,937 | -€24,663 | -€33,753 | -€17,139 |
| Capital Expenditures | -€1 | -€10 | -€252 | -€32 |
| Free Cash Flow | -€12,938 | -€24,673 | -€34,005 | -€17,171 |